An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma

被引:106
作者
Horlad, Hasita [1 ]
Ma, Chaoya [1 ]
Yano, Hiromu [1 ]
Pan, Cheng [1 ]
Ohnishi, Koji [1 ]
Fujiwara, Yukio [1 ]
Endo, Shinya [2 ]
Kikukawa, Yoshitaka [2 ]
Okuno, Yutaka [2 ]
Matsuoka, Masao [2 ,3 ]
Takeya, Motohiro [1 ]
Komohara, Yoshihiro [1 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Hematol, Kumamoto, Japan
[3] Kyoto Univ, Inst Virus Res, Lab Virus Control, Kyoto, Japan
关键词
CD163; macrophage; PD-L1; PD-L2; tumor-associated macrophages; TUMOR-ASSOCIATED MACROPHAGES; IMMUNE CHECKPOINT BLOCKADE; B7-H1; EXPRESSION; UP-REGULATION; PROGRESSION; LYMPHOCYTES; MPDL3280A;
D O I
10.1111/cas.13065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune escape and tolerance in the tumor microenvironment are closely involved in tumor progression, and are caused by T-cell exhaustion and mediated by the inhibitory signaling of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domaincontaining molecule-3. In the present study, we investigated the expression of the PD-1 ligand 1 (PD-L1) in a lymphoma microenvironment using paraffin-embedded tissue samples, and subsequently studied the detailed mechanism of upregulation of PD-L1 on macrophages using cultured human macrophages and lymphoma cell lines. We found that macrophages in lymphoma tissues of almost all cases of adult T-cell leukemia/lymphoma (ATLL), follicular lymphoma and diffuse large B-cell lymphoma expressed PD-L1. Cell culture studies showed that the conditioned medium of ATL-T and SLVL cell lines induced increased expression of PD-L1/2 on macrophages, and that this PD-L1/2 overexpression was dependent on activation of signal transducer and activator of transcription 3 (Stat3). Invitro studies including cytokine array analysis showed that IL-27 (heterodimer of p28 and EBI3) induced overexpression of PD-L1/2 on macrophages via Stat3 activation. Because lymphoma cell lines produced IL-27B (EBI3) but not IL-27p28, it was proposed that the IL-27p28 derived from macrophages and the IL-27B (EBI3) derived from lymphoma cells formed an IL-27 (heterodimer) that induced PD-L1/2 overexpression. Although the significance of PD-L1/2 expressions on macrophages in lymphoma progression has never been clarified, an IL-27-Stat3 axis might be a target for immunotherapy for lymphoma patients.
引用
收藏
页码:1696 / 1704
页数:9
相关论文
共 50 条
  • [31] Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma
    Paydas, Semra
    Bagir, Emine
    Seydaoglu, Gulsah
    Ercolak, Vehbi
    Ergin, Melek
    ANNALS OF HEMATOLOGY, 2015, 94 (09) : 1545 - 1552
  • [32] Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes
    Gompertz-Mattar, Matias
    Perales, Juan
    Sahu, Aditi
    Mondaca, Sebastian
    Gonzalez, Sergio
    Uribe, Pablo
    Navarrete-Dechent, Cristian
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (08) : 777 - 786
  • [33] Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis
    Zou, Ming-Xiang
    Peng, An-Bo
    Lv, Guo-Hua
    Wang, Xiao-Bin
    Li, Jing
    She, Xiao-Ling
    Jiang, Yi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (07): : 3274 - 3287
  • [34] Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
    Li, Kang
    Liu, Jun
    Wu, Lin
    Xiao, Yajie
    Li, Jia
    Du, Haijian
    Zhao, Zhikun
    Sun, Chao
    Zhao, Yongtian
    Yang, Jie
    Wu, Dongfang
    Zhao, Zhuxiang
    Chen, Bolin
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [35] GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma
    Yan, Jiuliang
    Zhou, Binghai
    Guo, Lei
    Chen, Zheng
    Zhang, Bo
    Liu, Shuang
    Zhang, Wentao
    Yu, Mincheng
    Xu, Yongfeng
    Xiao, Yongsheng
    Zhou, Jian
    Fan, Jia
    Li, Hui
    Ye, Qinghai
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (11): : 3705 - +
  • [36] STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
    Zerdes, Ioannis
    Wallerius, Majken
    Sifakis, Emmanouil G.
    Wallmann, Tatjana
    Betts, Stina
    Bartish, Margarita
    Tsesmetzis, Nikolaos
    Tobin, Nicholas P.
    Coucoravas, Christos
    Bergh, Jonas
    Rassidakis, George Z.
    Rolny, Charlotte
    Foukakis, Theodoros
    CANCERS, 2019, 11 (10)
  • [37] Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
    Gatalica, Zoran
    Snyder, Carrie
    Maney, Todd
    Ghazalpour, Anatole
    Holterman, Daniel A.
    Xiao, Nianqing
    Overberg, Peggy
    Rose, Inga
    Basu, Gargi D.
    Vranic, Semir
    Lynch, Henry T.
    Von Hoff, Daniel D.
    Hamid, Omid
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (12) : 2965 - 2970
  • [38] Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
    Cedres, S.
    Ponce-Aix, S.
    Pardo-Aranda, N.
    Navarro-Mendivil, A.
    Martinez-Marti, A.
    Zugazagoitia, J.
    Sansano, I.
    Montoro, M. A.
    Enguita, A.
    Felip, E.
    LUNG CANCER, 2016, 96 : 1 - 6
  • [39] The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas
    Vagios, Stylianos
    Yiannou, Petros
    Giannikaki, Elpida
    Doulgeraki, Triada
    Papadimitriou, Christos
    Rodolakis, Alexandros
    Nonni, Afroditi
    Vlachos, Athanassios
    Pavlakis, Kitty
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (11) : 1419 - 1428
  • [40] Programmed-cell death ligand 1 (PD-L1) expression in equine sarcoids and squamous cell carcinoma
    Pimenta, Jose
    Prada, Justina
    Pires, Isabel
    Cotovio, Mario
    OPEN VETERINARY JOURNAL, 2024, 14 (06) : 1476 - 1482